Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent, Refractory, or High Risk Leukemias”

155 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 155 results

Testing effectiveness (Phase 2)WithdrawnNCT02420938
What this trial is testing

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Who this might be right for
Leukemia
M.D. Anderson Cancer Center
Not applicableStudy completedNCT00006342
What this trial is testing

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

Who this might be right for
Brain and Central Nervous System TumorsLymphoma
Duke University 19
Early research (Phase 1)Study completedNCT00588991
What this trial is testing

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Who this might be right for
Adult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+20 more
National Cancer Institute (NCI) 12
Not applicableActive Not RecruitingNCT02670525
What this trial is testing

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Who this might be right for
Recurrent, Refractory, or High Risk LeukemiasMatched Targeted Therapy
Dana-Farber Cancer Institute 338
Testing effectiveness (Phase 2)Study completedNCT00047021
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Case Comprehensive Cancer Center 3
Early research (Phase 1)Ended earlyNCT06343376
What this trial is testing

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+11 more
Roswell Park Cancer Institute 1
Testing effectiveness (Phase 2)Ended earlyNCT00818649
What this trial is testing

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
LeukemiaMyelodysplastic Syndrome
Masonic Cancer Center, University of Minnesota 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT03672539
What this trial is testing

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 50
Early research (Phase 1)Study completedNCT00002588
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

Who this might be right for
Leukemia
Case Comprehensive Cancer Center 30
Early research (Phase 1)Active Not RecruitingNCT05564650
What this trial is testing

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome
Thomas Jefferson University 6
Not applicableStudy completedNCT00716911
What this trial is testing

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
City of Hope Medical Center 100
Testing effectiveness (Phase 2)Ended earlyNCT03404193
What this trial is testing

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm+12 more
M.D. Anderson Cancer Center 235
Early research (Phase 1)WithdrawnNCT00521261
What this trial is testing

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT02115295
What this trial is testing

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Who this might be right for
Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center 508
Testing effectiveness (Phase 2)Study completedNCT00683046
What this trial is testing

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Who this might be right for
Acute Myelogenous LeukemiaLymphoid LeukemiaChronic Myelogenous Leukemia+6 more
University of Chicago 204
Early research (Phase 1)Study completedNCT00988715
What this trial is testing

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePreviously Treated Myelodysplastic Syndrome+6 more
Fred Hutchinson Cancer Center 17
Early research (Phase 1)Looking for participantsNCT05829226
What this trial is testing

Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Who this might be right for
AML, Adult RecurrentMDS
PureTech 90
Testing effectiveness (Phase 2)WithdrawnNCT05367401
What this trial is testing

Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT00003397
What this trial is testing

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Maryland, Baltimore 25
Testing effectiveness (Phase 2)Study completedNCT03128359
What this trial is testing

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Who this might be right for
Acute LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center 38
Load More Results